Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-20 | 2024-06 | 0 | N/A | N/A | N/A |
2024-07-01 | 2024-03 | 0 | N/A | N/A | N/A |
2023-02-28 | 2022-12 | -0.19 | N/A | N/A | N/A |
2022-11-08 | 2022-09 | -0.25 | -0.2 | 0.05 | 20.00% |
2022-08-15 | 2022-06 | -0.23 | -0.31 | -0.08 | -34.78% |
2022-05-05 | 2022-03 | 0 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-02 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-03-25 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-09 | HC Wainwright & Co. | Upgrade | Buy | |
2021-01-21 | Alliance Global Partners | Upgrade | Buy | |
2020-07-31 | HC Wainwright & Co. | Upgrade | Buy | |
2020-05-26 | Dawson James | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-09-12 | ABG MANAGEMENT, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2021-03-15 | ASGHAR NAJJAM | Chief Financial Officer | 56.97K | Stock Award(Grant) |
2018-01-23 | ASIA PACIFIC MEDTECH BVI, LTD. | Beneficial Owner of more than 10% of a Class of Security | 8.62M | Sale |
2020-12-15 | FOLLOWWILL DORMAN | Director | 2.13K | Sale |
2021-12-26 | JANDA KIM D | Director | 3.00K | Sale |
2022-12-20 | JI HENRY H | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | State Street Corporation | 50.64M | 15.56M | 10.73% |
2022-12-30 | Blackrock Inc. | 39.42M | 12.11M | 8.35% |
2022-12-30 | Vanguard Group, Inc. (The) | 29.54M | 9.08M | 6.26% |
2022-12-30 | Geode Capital Management, LLC | 8.91M | 2.74M | 1.89% |
2022-12-30 | B. Riley Financial, Inc. | 5.22M | 1.60M | 1.11% |
2022-12-30 | B. Riley Securities, Inc. | 5.22M | 1.60M | 1.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 40.89M | 12.56M | 8.66% |
2022-09-29 | Vanguard Total Stock Market Index Fund | 12.84M | 3.95M | 2.72% |
2022-12-30 | iShares Russell 2000 ETF | 10.36M | 3.18M | 2.20% |
2022-09-29 | Vanguard Extended Market Index Fund | 5.51M | 1.69M | 1.17% |
2022-12-30 | Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh | 4.27M | 1.31M | 0.91% |
2022-12-30 | iShares Russell 2000 Value ETF | 4.11M | 1.26M | 0.87% |
Split | Date |
---|---|
0.04 : 1 | 2013-08-01 |
0.1 : 1 | 2008-10-07 |
-
RECORD THE CALL... total rubbish...He has no business talking...
-
Just finished with conference...ZERO info of any import.
-
-
-
-
-
The biggest relief I’ve felt in months (when it comes to stocks) was selling SRNE, and putting that towards AAPL pre-split. Reading the exact same comments here for months is maddening.
-
-
Just bought more to average down again
-
Just bought more to average down
-
Get our now. Fair market value around 5. That is still greater than 100 percent higher than where SRNE was prior to the pandemic and their ability to pump on fake COVID treatments and diagnostics. Don’t trust the CEO. Where is he from by the way? Just asking.
-
-
In my short investing career, I have learned the hard way that the management, particularly the CEO, DOES matter! It’s not good enough to have a company that sounds good, you have to have legitimate people running the company. That is why I don’t invest in companies like SRNE long term. Sure, try to catch a pump once in a while but this is not the type of company to trust your capital for the long term.
-
My family left me for losing all of our money. $SRNE
-
-
-
-
-
$SRNE complete piece of shit and trash.